Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Pediatric Subjects Aged 0 to < 18 Years With Late-onset Pompe Disease

NCT03911505 is registered in ClinicalTrials.gov with Amicus Therapeutics as lead sponsor.

NCT NCT03911505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03911505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study of the Safety, Pharmacokinetics, Efficacy, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa/Miglustat in Pediatric Subjects Aged 0 to < 18 Years With Late-onset Pompe Disease
Lead sponsor
Amicus Therapeutics
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 13, 2020
Completion date
September 30, 2027
Enrollment
21 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

pompe disease (late-onset)